Publications database

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis and rising incidence. Late detection and limited responsiveness to standard treatment translates into a 5-year overall survival of less than 12%. [...]

In the originally published version of this article, the t-SNE plot colouredby gene expression, labelled “Cdkn1a” (p21) in Extended Data Fig. 2e,was incorrect and instead showed “Cdkn1b” (p27). [...]

The LIM kinases (LIMK1/2) are key mediators in signaling cascades that regulate actin cytoskeleton dynamics via cofilin phosphorylation. Dysregulation of these pathways and overexpression of LIMKs are implicated in disease development, including cancer, Fragile X syndrome, and glaucoma. [...]

In this prospective cross-over study, the precision of manual correction of the clinical target volume (CTV) during online-adaptive radiotherapy (ART) of patients with bladder cancer was investigated in dependence on the input of applied computational algorithms.Online-adaptive-radiation therapy (ART) fractions were analysed from a prospective registry as a component of a trimodality treatment for bladder cancer. The CBCT-guided adaptive radiation therapy (CBCTgART) workflow uses a CBCT acquired at the beginning of a treatment session (CBCT1) to update the target volume contours of the planning CT (pCT) on the current anatomy of the day. [...]

Human TAPBPR is known to function as a Major Histocompatibility Complex class I (MHC-I) peptide exchange catalyst that shapes the peptide repertoire presented to immune cells. However, investigations characterizing TAPBPR from other species are limited. [...]

Immune checkpoint inhibitors have revolutionized cancer therapy, and their unintended side effects relate largely to inducing autoimmunity; effects on vascular functions have only rarely been observed so far. In this issue of Cancer Discovery, a puzzling finding is reported that has divergent clinical implications: PD-1 inhibitors make cytotoxic T lymphocytes secrete a Wnt pathway suppressor to the blood that opens the blood-brain barrier, both allowing circulating tumor cells to enter the brain and a chemotherapeutic to better reach tumor cells in brain metastases. [...]

As radiopharmaceutical therapy (RPT) expands beyond neuroendocrine tumors and prostate cancer, it is important to understand the U.S. Food and Drug Administration (FDA) approval process and to establish a shared vocabulary for effective communication. [...]

Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. [...]

The purpose of this study was to examine whether Ki67-scores have a predictive significance for pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer.This retrospective, bi-centric cohort study focused on HER2-positive early breast cancer patients undergoing neoadjuvant chemotherapy from 2015 to 2023. Multivariable logistic regression was used to find independent association between various clinical parameters, including Ki67, and pCR. [...]